STOCK TITAN

Esperion Therapeutics, Inc. - $ESPR STOCK NEWS

Welcome to our dedicated page for Esperion Therapeutics news (Ticker: $ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Esperion Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Esperion Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Esperion Therapeutics, Inc.

Nasdaq:ESPR

ESPR Rankings

ESPR Stock Data

390.17M
183.65M
0.45%
39.06%
10.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ANN ARBOR

About ESPR

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.